Hologic, Inc. (NASDAQ:HOLX) Shares Purchased by Plato Investment Management Ltd

Plato Investment Management Ltd increased its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 20,295.7% during the second quarter, HoldingsChannel reports. The fund owned 4,691 shares of the medical equipment provider’s stock after buying an additional 4,668 shares during the period. Plato Investment Management Ltd’s holdings in Hologic were worth $348,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in Hologic in the fourth quarter valued at $217,529,000. Cetera Investment Advisers grew its holdings in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider’s stock valued at $1,595,000 after purchasing an additional 13,380 shares during the last quarter. Nordea Investment Management AB grew its holdings in Hologic by 1.3% in the first quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider’s stock valued at $116,797,000 after purchasing an additional 19,680 shares during the last quarter. Pinebridge Investments L.P. grew its holdings in Hologic by 39.8% in the fourth quarter. Pinebridge Investments L.P. now owns 397,251 shares of the medical equipment provider’s stock valued at $28,384,000 after purchasing an additional 113,050 shares during the last quarter. Finally, Clearbridge Investments LLC grew its holdings in Hologic by 51.4% in the first quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider’s stock valued at $40,430,000 after purchasing an additional 176,006 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ HOLX opened at $82.70 on Tuesday. The business’s 50-day moving average price is $80.36 and its 200 day moving average price is $76.92. Hologic, Inc. has a twelve month low of $64.02 and a twelve month high of $84.67. The company has a market capitalization of $19.30 billion, a PE ratio of 42.19, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.04. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.53% and a net margin of 17.59%. The firm’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.93 earnings per share. On average, research analysts predict that Hologic, Inc. will post 4.09 earnings per share for the current year.

Insiders Place Their Bets

In other Hologic news, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the sale, the insider now directly owns 10,476 shares in the company, valued at $858,927.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Hologic news, Director Christiana Stamoulis sold 9,039 shares of the company’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $79.50, for a total transaction of $718,600.50. Following the completion of the sale, the director now directly owns 45,472 shares in the company, valued at $3,615,024. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Benjamin Jordan Cohn sold 5,093 shares of the company’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $81.99, for a total value of $417,575.07. Following the sale, the insider now owns 10,476 shares of the company’s stock, valued at $858,927.24. The disclosure for this sale can be found here. Insiders sold 18,280 shares of company stock worth $1,469,973 over the last three months. 1.75% of the stock is owned by insiders.

Wall Street Analyst Weigh In

HOLX has been the topic of several research reports. StockNews.com raised Hologic from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 10th. Stephens reissued an “overweight” rating and issued a $92.00 target price on shares of Hologic in a report on Tuesday, July 30th. JPMorgan Chase & Co. upped their price objective on Hologic from $91.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, July 30th. Needham & Company LLC restated a “buy” rating and issued a $90.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Evercore ISI upped their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Tuesday, July 30th. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $87.60.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.